Literature DB >> 9310112

Dermal IgG deposits and increase of mast cells in patients with fibromyalgia--relevant findings or epiphenomena?

S Eneström1, A Bengtsson, T Frödin.   

Abstract

Skin biopsies from 25 patients with fibromyalgia, 5 healthy controls, 8 patients with rheumatoid arthritis, and 9 patients with local chronic pain after whiplash injury, were examined for the occurrence of IgG deposits and collagen types, using direct and indirect immunofluorescence, and for dermal connective tissue mast cells, using semithin Epon sections. Fibromyalgia skin biopsies had significantly higher values of IgG deposits in the dermis and vessel walls and showed a higher reactivity for collagen III. They also had a higher mean number of mast cells. There was a correlation between the percentage of damaged/degranulated mast cells and the individual IgG immunofluorescence scores. These findings support the hypothesis of neurogenic inflammation involvement in fibromyalgia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310112     DOI: 10.3109/03009749709105321

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  18 in total

1.  Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia.

Authors:  Kim D Jones; Terri Gelbart; Thomas C Whisenant; Jill Waalen; Tony S Mondala; David N Iklé; Daniel R Salomon; Robert M Bennett; Sunil M Kurian
Journal:  Clin Exp Rheumatol       Date:  2016-02-12       Impact factor: 4.473

2.  Nociceptive aspects of fibromyalgia.

Authors:  A A Larson; K J Kovács
Journal:  Curr Pain Headache Rep       Date:  2001-08

3.  Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients.

Authors:  Ignacio Blanco; Nana Béritze; Mario Argüelles; Victoriano Cárcaba; Fernando Fernández; Sabina Janciauskiene; Katerina Oikonomopoulou; Frederick J de Serres; Enrique Fernández-Bustillo; Morley D Hollenberg
Journal:  Clin Rheumatol       Date:  2010-04-30       Impact factor: 2.980

4.  Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial.

Authors:  Dennis C Ang; Janna Hilligoss; Timothy Stump
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

Review 5.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

6.  Dermatologic manifestations of fibromyalgia.

Authors:  Valerie Laniosz; David A Wetter; Desiree A Godar
Journal:  Clin Rheumatol       Date:  2014-01-14       Impact factor: 2.980

Review 7.  Status of immune mediators in fibromyalgia.

Authors:  Ali Gur; Pelin Oktayoglu
Journal:  Curr Pain Headache Rep       Date:  2008-06

8.  Characteristic electron microscopic findings in the skin of patients with fibromyalgia: preliminary study.

Authors:  Seong-Ho Kim; Dong Hoon Kim; Dong-Ho Oh; Daniel J Clauw
Journal:  Clin Rheumatol       Date:  2007-10-03       Impact factor: 2.980

Review 9.  Hypersensitivity in muscle pain syndromes.

Authors:  Karl G Henriksson
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 10.  Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome.

Authors:  Geoffrey Littlejohn
Journal:  Nat Rev Rheumatol       Date:  2015-08-04       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.